Evidence map›Paper›PMID 41097384›Full record

ArticleMolecules (Basel, Switzerland)2025

Safety, Pharmacokinetics, Translational and Molecular Mechanistic Insights on the Prostate Cancer Recurrence Suppressor Pseurotin A.

Oliver C McGehee, Hassan Y Ebrahim, Sharon Meyer, Nehal A Ahmed, Chandra Mohan Reddy Muthumula, Dalal Dawud, Judy A King, Amal Kaddoumi, Khalid A El Sayed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Oliver C McGeheeDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Hassan Y EbrahimDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0001-9057-4582
Sharon MeyerDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Nehal A AhmedDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Chandra Mohan Reddy MuthumulaDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0002-8200-4616
Dalal DawudDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.
Judy A KingDeBusk College of Osteopathic Medicine, Lincoln Memorial University, 9737 Cogdill Road, Knoxville, TN 37932, USA.ORCID 0000-0001-9276-4275
Amal KaddoumiDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, 1201 Goss Lane, Augusta, GA 30912, USA.
Khalid A El SayedDepartment of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, 1800 Bienville Drive, Monroe, LA 71201, USA.ORCID 0000-0002-1456-4064

Funding

Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppressionR21CA263290 · NCI · UNIVERSITY OF LOUISIANA AT MONROE · PI EL SAYED, KHALID A · 2022 to 2023
$344k
National Cancer Institute, NIH-USA R21CA263290
6 · The paper itself

Abstract

Elevated cholesterol levels play important mitogenic roles. Pseurotin A (PsA) is a fermentation product that has recently been reported as a dual inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) secretion and protein-protein interaction (PPI) with the LDLR. PsA showed a high acute safety profile and therapeutic potential against metastatic castration-resistant prostate cancer (mCRPC). The study aims to uncover the chronic safety, distribution, and anti-mCRPC genomic and molecular mechanistic insights of PsA. A 90-day chronic safety assessment of PsA up to 80 mg/kg in

Indexed as

Neoplasm Recurrence, LocalProstatic Neoplasms, Castration-ResistantAnimalsBenzamidesCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleMiceMice, NudeNitrilesXenograft Model Antitumor AssaysBenzamidesNitrilesdifferentially expressed genesPCSK9prostate cancerpseurotin ArecurrenceRNA-sequencingubiquitin-proteasome system

Identifiers

PMID41097384
PMCPMC12525728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.